Claude Derbin

Title: Claude Derbin: Innovator in Angiogenesis Research

Introduction

Claude Derbin is a notable inventor based in Gif sur Yvette, France. He has made significant contributions to the field of biomedical research, particularly in the area of angiogenesis. His work focuses on the development of peptides that can inhibit vascular endothelial growth factor (VEGF)-mediated angiogenesis, which is crucial for understanding and treating various diseases.

Latest Patents

Claude Derbin holds a patent for "Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof." This invention provides peptides that interact with VEGF, inhibiting its interaction with KDR or anti-VEGF antibodies. This inhibition is vital for preventing VEGF-mediated angiogenesis and related diseases. The patent also includes polynucleotides encoding these peptides, vectors containing the polynucleotides, and pharmaceutical compositions that utilize these peptides.

Career Highlights

Claude Derbin is affiliated with the prestigious Institut Pasteur, where he conducts his research. His work has been instrumental in advancing the understanding of angiogenesis and its implications in various medical conditions. With a focus on innovative solutions, he continues to contribute to the scientific community.

Collaborations

Claude has collaborated with esteemed colleagues, including Roselyne Tournaire and Caroline Demangel. These partnerships have enhanced the research efforts at Institut Pasteur and have led to significant advancements in the field.

Conclusion

Claude Derbin's innovative work in the field of angiogenesis research highlights the importance of peptides in medical science. His contributions through patents and collaborations continue to pave the way for new therapeutic approaches.